Explore
Validate
LearnAF1138
antibody from R&D Systems
Targeting: SIGLEC7
CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF1138 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Siglec-7/CD328 Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human Siglec-7/CD328 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human (rh) Siglec-9 is observed and approximately 5% cross-reactivity with recombinant mouse Siglec-E, rhSiglec-6, and rhSiglec-8 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q9Y286- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes.
Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes.
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides.
Dharmadhikari G, Stolz K, Hauke M, Morgan NG, Varki A, de Koning E, Kelm S, Maedler K
Scientific reports 2017 Apr 5;7:45319
Scientific reports 2017 Apr 5;7:45319
Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes.
Varchetta S, Brunetta E, Roberto A, Mikulak J, Hudspeth KL, Mondelli MU, Mavilio D
PloS one 2012;7(9):e45821
PloS one 2012;7(9):e45821
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides.
Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E, Pino M, Erkizia I, Glass B, Clotet B, Keppler OT, Telenti A, Kräusslich HG, Martinez-Picado J
PLoS biology 2012;10(12):e1001448
PLoS biology 2012;10(12):e1001448
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Adhesion Mediated by Siglec-7 and Neutralization by Human Siglec-7 Antibody. Recombinant Human Siglec-7 Fc Chimera (Catalog # 1138-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-7 Fc Chimera (1.5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human Siglec-7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1138). The ND50 is typically 0.3-0.9 µg/mL.
